Pharmacy
The FTC will launch an inquiry into the prescription drug middleman industry.
Increases in consolidation and alignment between commercial health plans and pharmacy benefit managers have resulted in a series of business practices designed to steer patients to insurer-affiliated pharmacies and away from patients鈥 longstanding providers to the detriment of patient care.
The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.
As recommended by the AHA, the Food and Drug Administration proposed revising 2016 draft guidance to allow hospital and health system pharmacies that are not outsourcing facilities to distribute compounded drug products to any health care facility in the same system without first receiving a valid鈥
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released by the House Committee on Oversight and Reform.
SIF Webinar: State White Bagging and State Legislation resources.
Regulators should prohibit health insurers from preventing hospitals and physicians in their networks from directly acquiring and storing drugs used in patient care, according to a white paper released today by AHA.
Letter to Centers for Medicare & Medicaid Services, expressing deep concerns regarding a series of UnitedHealthcare health plan coverage policies.
COVID-19 continues to dramatically impact the short- and long-term strategies of hospitals and health systems.
.webreplay{
border: solid 2px #777;
padding: 15px 5px;
margin: 0 0 10px 15px;
}
@media (min-width:360px){
.webreplay{
min-width: 290px;
float: right;
}
}
On-demand Webinar
MktoForms2.loadForm("//app-sj20.marketo.com", "734-ZTO-041", 5774);
Pharmacy Benefit鈥